var data={"title":"Benzocaine, butamben, and tetracaine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Benzocaine, butamben, and tetracaine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/111961?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=benzocaine-butamben-and-tetracaine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Benzocaine, butamben, and tetracaine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033396\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cetacaine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033493\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Local Anesthetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033519\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Anesthesia:</b> Topical: Cetacaine:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spray: Apply for &le;1 second; use of sprays &gt;2 seconds is contraindicated. <b>Note:</b> Spray provides ~200 mg/second</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel: Apply  200 mg (~<sup>1</sup>/<sub>4</sub> to <sup>1</sup>/<sub>2</sub> inch); application of &gt;400 mg (&gt;1 inch) is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liquid: Apply 200 mg (~0.2 mL); application of &gt;400 mg (~0.4 mL) is contraindicated</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033518\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">Dose has not been established; dose reduction is suggested</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033520\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Dose reduction is suggested; refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23325438\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23325439\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033523\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aerosol, spray, topical [kit]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cetacaine: Benzocaine 14%, butamben 2%, and tetracaine hydrochloride 2% (56 g) [delivers benzocaine 28 mg, butamben 4 mg, and tetracaine hydrochloride 4 mg per second; contains benzalkonium chloride, chlorofluorocarbon; packaged with cannula assortment]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aerosol, spray, topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cetacaine: Benzocaine 14%, butamben 2%, and tetracaine hydrochloride 2% (5g, 20 g, 56 g [DSC]) [delivers benzocaine 28 mg, butamben 4 mg, and tetracaine hydrochloride 4 mg per second; contains benzalkonium chloride, chlorofluorocarbon; packaged with cannula]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel, topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cetacaine: Benzocaine 14%, butamben 2%, and tetracaine hydrochloride 2% (32 g) [delivers benzocaine 28 mg, butamben 4 mg and tetracaine hydrochloride 4 mg per pump actuation ~ 0.25 inch (6.5 mm) x 0.5 inch (13 mm) long application; contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liquid, topical [kit]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cetacaine: Benzocaine 14%, butamben 2%, and tetracaine hydrochloride 2% (14 g, 30 g) [provides benzocaine 28 mg, butamben 4 mg, and tetracaine hydrochloride 4 mg per 6-7 drops (0.2 mL); contains benzalkonium chloride; packaged with syringes and applicator tips]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liquid, topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cetacaine: Benzocaine 14%, butamben 2%, and tetracaine hydrochloride 2% (14 g, 30 g) [provides benzocaine 28 mg, butamben 4 mg, and tetracaine hydrochloride 4 mg per 6-7 drops (0.2 mL); contains benzalkonium chloride]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033491\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033521\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid application to large areas of broken skin, especially in children. When possible, apply to clean, dry area, however, tissue need not be dried prior to application. When administering a spray formulation, the number of sprays administered and the length of each spray should be monitored and recorded.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Spray: Apply directly to the site where pain or gag control is desired for procedure (ear, nose, mouth, pharynx, larynx, trachea, bronchi, esophagus, vagina, or rectum).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel: Spread thinly and evenly over application area using a cotton swab.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liquid: Apply with cotton applicator or directly onto tissue; do not hold applicator in position for prolonged periods of time.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033494\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Topical anesthetic to control pain in surgical or endoscopic procedures, or other procedures in the ear, nose, mouth, pharynx, larynx, trachea, bronchi, and esophagus (may also be used for vaginal or rectal procedure, when feasible); anesthetic for accessible mucous membranes except for the eyes; to control pain or gagging (spray only)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033501\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. Also see Benzocaine and Tetracaine monographs. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Contact dermatitis (eg, erythema, local oozing, localized vesiculation, pruritus), eschar, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis (rare), hypersensitivity reaction (rare) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033497\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to benzocaine, butamben, tetracaine, or any component of the formulation; ophthalmic use; cholinesterase deficiencies; large areas of denuded or inflamed tissue; administration in excess of product labeling; administration via injection; application under dentures or cotton rolls</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033498\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergic reaction:  Localized reactions, including erythema, pruritus, vesiculation, and eschar may occur; most commonly following prolonged or repeated use. Discontinue if rash, urticaria, edema or other allergic response develop at application site. Prolonged use should only be done under continual medical supervision.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Methemoglobinemia: Has been reported following topical benzocaine use (rare), particularly with higher concentration (14% to 20%) spray formulations applied to the mouth or mucous membranes. The classical clinical finding of methemoglobinemia is chocolate brown-colored arterial blood. However, suspected cases should be confirmed by co-oximetry, which yields a direct and accurate measure of methemoglobin levels. Standard pulse oximetry readings or arterial blood gas values are not reliable. Clinically-significant methemoglobinemia requires immediate treatment. Use caution with breathing problems (asthma, bronchitis, emphysema, in smokers), inflamed/damaged mucosa, heart disease, children &lt;6 months of age, and hemoglobin or enzyme abnormalities (glucose-6-phosphate dehydrogenase deficiency, hemoglobin-M disease, NADH-methemoglobin reductase deficiency, pyruvate-kinase deficiency). Alternatives to benzocaine sprays, such as topical lidocaine preparations, should be considered for patients at higher risk of this reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Acutely ill patients: Use with caution in acutely ill patients; dose adjustment is suggested. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Debilitated patients: Use with caution in debilitated patients; dose adjustment is suggested. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly; dose adjustment is suggested. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Use with caution in very young patients; dose adjustment is suggested.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: For topical use only. Use under dentures or cotton rolls is contraindicated; retention of active ingredients may cause escharotic effect.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Topical application: When topical anesthetics are used prior to cosmetic or medical procedures, the lowest amount of anesthetic necessary for pain relief should be applied. High systemic levels and toxic effects (eg, methhemoglobinemia, irregular heart beats, respiratory depression, seizures, death) have been reported in patients who (without supervision of a trained professional) have applied topical anesthetics in large amounts (or to large areas of the skin), left these products on for prolonged periods of time, or have used wraps/dressings to  cover the skin following application.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298838\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6218303\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8818&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methemoglobinemia Associated Agents: Tetracaine (Topical) may enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033495\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Safety has not been established; use is not recommended during early pregnancy unless the potential benefits outweigh the risks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3882051\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;\">Monitor patients for signs and symptoms of methemoglobinemia such as pallor, cyanosis, nausea, muscle weakness, dizziness, confusion, agitation, dyspnea and tachycardia. The classical clinical finding of methemoglobinemia is chocolate brown-colored arterial blood. However, suspected cases should be confirmed by co-oximetry, which yields a direct and accurate measure of methemoglobin levels. Standard pulse oximetry readings or arterial blood gas values are not reliable. Clinically significant methemoglobinemia requires immediate treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033509\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reversible blockage of initiation and conduction of nerve impulses by decreasing the neuronal membrane&rsquo;s permeability to sodium ions</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3033511\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Also see individual monographs for Benzocaine and Tetracaine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: ~30 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 30-60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Plasma via hydrolysis by cholinesterase to inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (as inactive metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26597083\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol</b> (Cetacaine External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2-2-14% (5 g): $63.02</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Cetacaine (benzocaine/butamben/tetracaine) [prescribing information]. Pennsauken, NJ: Cetylite Industries Inc; July 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8818 Version 78.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F3033396\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F3033493\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F3033519\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F3033518\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3033520\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F23325438\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F23325439\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F3033523\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F3033491\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F3033521\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F3033494\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3033501\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F3033497\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3033498\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298838\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6218303\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3033495\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3882051\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F3033509\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F3033511\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F26597083\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8818|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=benzocaine-butamben-and-tetracaine-patient-drug-information\" class=\"drug drug_patient\">Benzocaine, butamben, and tetracaine: Patient drug information</a></li></ul></div></div>","javascript":null}